FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Masahiko Nishiyama

Research Profile

Disorders

Living Beings

Chemicals & Drugs

Anatomy

Tumor Cells, Cultured

Procedures

Physiology

Co-author Network

Publications

TOP 3
Marina Arifin; Keiji Tanimoto; Andika Chandra Putra; Eiso Hiyama; Masahiko Nishiyama; Keiko Hiyama
Carcinogenesis and cellular immortalization without persistent inactivation of p16/Rb pathway in lung cancer.
Shoichi Fumoto; Keiji Tanimoto; Eiso Hiyama; Tsuyoshi Noguchi; Masahiko Nishiyama; Keiko Hiyama
EMP3 as a candidate tumor suppressor gene for solid tumors.
Shoichi Fumoto; Keiko Hiyama; Keiji Tanimoto; Tsuyoshi Noguchi; Jun Hihara; Eiso Hiyama; Takuya Noguchi; Masahiko Nishiyama
EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Masahiko Nishiyama (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Marina Arifin; Keiji Tanimoto; Andika Chandra Putra; Eiso Hiyama; Masahiko Nishiyama; Keiko Hiyama
Carcinogenesis and cellular immortalization without persistent inactivation of p16/Rb pathway in lung cancer.
International journal of oncology 2010;36(5):1217-27.
2009: Shoichi Fumoto; Keiji Tanimoto; Eiso Hiyama; Tsuyoshi Noguchi; Masahiko Nishiyama; Keiko Hiyama
EMP3 as a candidate tumor suppressor gene for solid tumors.
Expert opinion on therapeutic targets 2009;13(7):811-22.
2009: Shoichi Fumoto; Keiko Hiyama; Keiji Tanimoto; Tsuyoshi Noguchi; Jun Hihara; Eiso Hiyama; Takuya Noguchi; Masahiko Nishiyama
EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma.
Cancer letters 2009;274(1):25-32.
2008: Keiko Hiyama; Keiji Tanimoto; Youhei Nishimura; Momomi Tsugane; Ikuko Fukuba; Yusuke Sotomaru; Eiso Hiyama; Masahiko Nishiyama
Exploration of the genes responsible for unlimited proliferation of immortalized lung fibroblasts.
Experimental lung research 2008;34(7):373-90.
2008: H Nakamura; Keiji Tanimoto; Keiko Hiyama; Mayu Yunokawa; Takeshi Kawamoto; Yukio Kato; Koji Yoshiga; Lorenz Poellinger; Eiso Hiyama; Masahiko Nishiyama
Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2.
Oncogene 2008;27(30):4200-9.
2008: Shoichi Fumoto; Tatsushi Shimokuni; Keiji Tanimoto; Keiko Hiyama; Keiko Otani; Megu Ohtaki; Jun Hihara; Kazuhiro Yoshida; Eiso Hiyama; Tsuyoshi Noguchi; Masahiko Nishiyama
Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response.
International journal of oncology 2008;32(2):413-23.
2007: Marina Arifin; Keiko Hiyama; Keiji Tanimoto; Wiwien Heru Wiyono; Eiso Hiyama; Masahiko Nishiyama
EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung.
Oncology reports 2007;17(6):1405-11.
2007: Mayu Yunokawa; Keiji Tanimoto; Hideaki Nakamura; Nobutaka Nagai; Yoshiki Kudo; Takeshi Kawamoto; Yukio Kato; Eiso Hiyama; Keiko Hiyama; Masahiko Nishiyama
Differential regulation of DEC2 among hypoxia-inducible genes in endometrial carcinomas.
Oncology reports 2007;17(4):871-8.
2007: Keiji Tanimoto; Mika Kaneyasu; Tatsushi Shimokuni; Keiko Hiyama; Masahiko Nishiyama
Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro.
Pharmacogenetics and genomics 2007;17(1):1-10.
2006: Eiso Hiyama; Hiroaki Yamaoka; Arata Kamimatsuse; Yoshiyuki Onitake; Keiko Hiyama; Masahiko Nishiyama; Taijiro Sueda
Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients.
Journal of pediatric surgery 2006;41(12):2032-6.
2006: Kazuhiro Yoshida; Motoki Ninomiya; Norihisa Takakura; Naoki Hirabayashi; Wataru Takiyama; Yuji Sato; Satoru Todo; Masanori Terashima; Mitsukazu Gotoh; Jyunnichi Sakamoto; Masahiko Nishiyama
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 1):3402-7.
2006: Tatsushi Shimokuni; Keiji Tanimoto; Keiko Hiyama; Keiko Otani; Megu Ohtaki; Jun Hihara; Kazuhiro Yoshida; Tsuyoshi Noguchi; Katsunobu Kawahara; Shoji Natsugoe; Takashi Aikou; Yasushi Okazaki; Yoshihide Hayashizaki; Yuji Sato; Satoru Todo; Eiso Hiyama; Masahiko Nishiyama
Chemosensitivity prediction in esophageal squamous cell carcinoma: novel marker genes and efficacy-prediction formulae using their expression data.
International journal of oncology 2006;28(5):1153-62.
2006: Wataru Yasui; Jaffer A Ajani; Masahiko Nishiyama; Atsushi Ohtsu; Eiichi Tahara
Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005.
Cancer science 2006;97(4):328-31.
2006: Masaaki Komatsu; Keiko Hiyama; Keiji Tanimoto; Mayu Yunokawa; Keiko Otani; Megu Ohtaki; Eiso Hiyama; Junzo Kigawa; Michitaka Ohwada; Mitsuaki Suzuki; Nobutaka Nagai; Yoshiki Kudo; Masahiko Nishiyama
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers.
Molecular cancer therapeutics 2006;5(3):767-75.
2005: Masahiko Nishiyama
[Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].
Gan to kagaku ryoho. Cancer & chemotherapy 2005;32(12):1902-7.
2005: Keiko Hiyama; Keiko Otani; Megu Ohtaki; Kenichi Satoh; Tsutomu Kumazaki; Tomoko Takahashi; Youji Mitsui; Yasushi Okazaki; Yoshihide Hayashizaki; Hideaki Omatsu; Takuya Noguchi; Keiji Tanimoto; Masahiko Nishiyama
Differentially expressed genes throughout the cellular immortalization processes are quite different between normal human fibroblasts and endothelial cells.
International journal of oncology 2005;27(1):87-95.
2005: Masahiko Nishiyama
Cancer pharmacogenomics: progress and obstacles toward the goal.
International journal of clinical oncology 2005;10(1):3-4.
2005: Kei Ukon; Keiji Tanimoto; Tatsushi Shimokuni; Takuya Noguchi; Keiko Hiyama; Hiroaki Tsujimoto; Masakazu Fukushima; Tetsuya Toge; Masahiko Nishiyama
Activator protein accelerates dihydropyrimidine dehydrogenase gene transcription in cancer cells.
Cancer research 2005;65(3):1055-62.
2004: Toshio Kuwai; Yasuhiko Kitadai; Shinji Tanaka; Tsuyoshi Kuroda; Takehiko Ochiumi; Shunji Matsumura; Naohide Oue; Wataru Yasui; Mika Kaneyasu; Keiji Tanimoto; Masahiko Nishiyama; Kazuaki Chayama
Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma.
Oncology reports 2004;12(5):1033-7.
2004: Takuya Noguchi; Keiji Tanimoto; Tatsushi Shimokuni; Kei Ukon; Hiroaki Tsujimoto; Masakazu Fukushima; Tsuyoshi Noguchi; Katsunobu Kawahara; Keiko Hiyama; Masahiko Nishiyama
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):7100-7.
2004: Tomotaka Tanaka; Keiji Tanimoto; Keiko Otani; Kenichi Satoh; Megu Ohtaki; Kazuhiro Yoshida; Tetsuya Toge; Hiroshi Yahata; Shinji Tanaka; Kazuaki Chayama; Yasushi Okazaki; Yoshihide Hayashizaki; Keiko Hiyama; Masahiko Nishiyama
Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes.
International journal of cancer. Journal international du cancer 2004;111(4):617-26.
2004: Tsutomu Kumazaki; Keiko Hiyama; Tomoko Takahashi; Hideaki Omatsu; Keiji Tanimoto; Takuya Noguchi; Eiso Hiyama; Youji Mitsui; Masahiko Nishiyama
Differential gene expressions during immortalization of normal human fibroblasts and endothelial cells transfected with human telomerase reverse transcriptase gene.
International journal of oncology 2004;24(6):1435-42.
2004: Kazuhiro Yoshida; Naoki Hirabayashi; Wataru Takiyama; Motoki Ninomiya; Norihisa Takakura; Jyunnichi Sakamoto; Masahiko Nishiyama; Tetsuya Toge
Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
Anticancer research 2004;24(3b):1843-51.
2003: Eiso Hiyama; Keiko Hiyama; Masahiko Nishiyama; Charles Patrick Reynolds; Jerry W Shay; Takashi Yokoyama
Differential gene expression profiles between neuroblastomas with high telomerase activity and low telomerase activity.
Journal of pediatric surgery 2003;38(12):1730-4.
2003: Keiji Tanimoto; Koji Yoshiga; Hidetaka Eguchi; Mika Kaneyasu; Kei Ukon; Tsutomu Kumazaki; Naohide Oue; Wataru Yasui; Kazue Imai; Kei Nakachi; Lorenz Poellinger; Masahiko Nishiyama
Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance.
Carcinogenesis 2003;24(11):1779-83.
2003: Tsutomu Kumazaki; Masao Sasaki; Masahiko Nishiyama; Yasuhiro Teranishi; Hiroshi Sumida; Akira Eboshida; Youji Mitsui
Life span shortening of normal fibroblasts by overexpression of BCL-2: a result of potent increase in cell death.
Experimental cell research 2003;285(2):299-308.
2003: Wataru Yasui; Masahiko Nishiyama; Takashi Tsuruo; Eiichi Tahara
Molecular targeting therapy for cancer: the Twelfth International Symposium of the Hiroshima Cancer Seminar, November 2002.
Cancer science 2003;94(2):221-3.
2003: Kazuhiro Yoshida; Kazuaki Tanabe; Hideaki Ueno; Kouji Ohta; Jun Hihara; Tetsuya Toge; Masahiko Nishiyama
Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2003;6 Suppl 1():82-9.
2003: Masao Sasaki; Tsutomu Kumazaki; Keiji Tanimoto; Masahiko Nishiyama
Bcl-2 in cancer and normal tissue cells as a prediction marker of response to 5-fluorouracil.
International journal of oncology 2003;22(1):181-6.
2002: Kazuko Miyazaki; Takeshi Kawamoto; Keiji Tanimoto; Masahiko Nishiyama; Hiroaki Honda; Yukio Kato
Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes.
The Journal of biological chemistry 2002;277(49):47014-21.
2002: Ji Seon Park; Wataru Yamamoto; Takashi Sekikawa; Masaaki Matsukawa; Ryo Okamoto; Masao Sasaki; Kei Ukon; Keiji Tanimoto; Tsutomu Kumazaki; Masahiko Nishiyama
Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers.
International journal of oncology 2002;20(2):333-8.
2002: Tsutomu Kumazaki; Masao Sasaki; Masahiko Nishiyama; Yasuhiro Teranishi; Hiroshi Sumida; Youji Mitsui
Effect of BCL-2 down-regulation on cellular life span.
Biogerontology 2002;3(5):291-300.
2002: Ryo Okamoto; Hiroshi Takano; Tatsunori Okamura; Ji-Seon Park; Keiji Tanimoto; Takashi Sekikawa; Wataru Yamamoto; Alex Sparreboom; Jaap Verweij; Masahiko Nishiyama
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Japanese journal of cancer research : Gann 2002;93(1):93-102.
2001: Ryo Okamoto; Hiroshi Takano; Takashi Sekikawa; T Tanaka; M Toyada; Kei Ukon; Keiji Tanimoto; Tsutomu Kumazaki; Masahiko Nishiyama
Unique action determinants of double acting topoisomerase inhibitor, TAS-103.
International journal of oncology 2001;19(5):921-7.
2001: Kazuhiro Yoshida; N Nishimoto; Y Kagawa; Jun Hihara; Hiroko Inoue; Ryungsa Kim; T Hirai; Masahiko Nishiyama; Tetsuya Toge
[A new therapeutic approach to advanced and recurrent gastric cancer by TS-1].
Gan to kagaku ryoho. Cancer & chemotherapy 2001;28(10):1403-12.
2001: I Hayashi; Masahiko Nishiyama
[Genome research and anticancer chemotherapy].
Gan to kagaku ryoho. Cancer & chemotherapy 2001;28(9):1183-9.
2000: S Murakami; Kazuhiro Yoshida; R Kin; N Nishimoto; Y Kagawa; Y Yano; Masahiko Nishiyama; T Hirai; Tetsuya Toge
[The clinical effect of low-dose FP (5-FU + low-dose CDDP) in patients with far advanced gastric cancer, and their quality of life].
Gan to kagaku ryoho. Cancer & chemotherapy 2000;27(6):853-8.
2000: Tetsuya Toge; H Nakazato; Masahiko Nishiyama; Koichi Hirata; Susumu Yamamitsu; M Sowa; Shigetoyo Saji
[Current status of "low-dose cisplatin-5-FU therapy" for solid tumors (2nd report)--from a nationwide questionnaire on its adverse effects].
Gan to kagaku ryoho. Cancer & chemotherapy 2000;27(4):549-58.
2000: Tatsunori Okamura; Kaoru Kurisu; Wataru Yamamoto; Hiroshi Takano; Masahiko Nishiyama
NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy.
International journal of oncology 2000;16(2):295-303.
1999: Masahiko Nishiyama; Wataru Yamamoto; Ji Seon Park; Ryo Okamoto; Hideaki Hanaoka; Hiroshi Takano; N Saito; M Matsukawa; T Shirasaka; M Kurihara
Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2620-8.
1999: K Suzuki; Wataru Yamamoto; Ji Seon Park; Hideaki Hanaoka; Ryo Okamoto; Y Kirihara; T Yorishima; Tatsunori Okamura; Tsutomu Kumazaki; Masahiko Nishiyama
Regulatory network of mitomycin C action in human colon cancer cells.
Japanese journal of cancer research : Gann 1999;90(5):571-7.
1999: Tsutomu Kumazaki; Youji Mitsui; K Hamada; Hiroshi Sumida; Masahiko Nishiyama
Detection of alternative splicing of fibronectin mRNA in a single cell.
Journal of cell science 1999;112 ( Pt 10)():1449-53.
1999: Y Kirihara; Wataru Yamamoto; Tetsuya Toge; Masahiko Nishiyama
Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells.
International journal of oncology 1999;14(3):551-6.
1997: Masahiko Nishiyama; K Suzuki; Tsutomu Kumazaki; Wataru Yamamoto; Tetsuya Toge; Tatsunori Okamura; Kaoru Kurisu
Molecular targeting of mitomycin C chemotherapy.
International journal of cancer. Journal international du cancer 1997;72(4):649-56.
1997: Kenjiro Aogi; Masahiko Nishiyama; R Kim; N Hirabayashi; Tetsuya Toge; A Mizutani; K Okada; H Sumiyoshi; Y Fujiwara; M Yamakido; T Kusano; T Andoh
Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential.
International journal of cancer. Journal international du cancer 1997;72(2):295-300.
1997: N Sakamoto; Tetsuya Toge; Masahiko Nishiyama
Tumor-specific synergistic therapy of mitomycin C: modulation of bioreductive activation.
Hiroshima journal of medical sciences 1997;46(2):67-73.
1997: Masahiko Nishiyama; Tetsuya Toge
Selection of adjuvant chemotherapy for gastric cancer using objective criteria.
Gan to kagaku ryoho. Cancer & chemotherapy 1997;24 Suppl 1():232-8.
1995: S Saeki; Masahiko Nishiyama; Tetsuya Toge
DT-diaphorase as a target enzyme for biochemical modulation of mitomycin C.
Hiroshima journal of medical sciences 1995;44(3):55-63.
1995: K Yoshida; H Kawami; Yoshiyuki Yamaguchi; Hiroki Kuniyasu; Masahiko Nishiyama; T Hirai; K Yanagihara; Eiichi Tahara; Tetsuya Toge
Retrovirally transmitted gene therapy for gastric carcinoma using herpes simplex virus thymidine kinase gene.
Cancer 1995;75(6 Suppl):1467-71.
1995: Masahiko Nishiyama; I Takashima; T Tanaka; K Yoshida; Tetsuya Toge; N Nagata; S Iwamori; Y Tamura
Carcinoembryonic antigen levels in the peritoneal cavity: useful guide to peritoneal recurrence and prognosis for gastric cancer.
World journal of surgery 1995;19(1):133-7; discussion 137.
1994: T Nishida; Shinji Tanaka; Ken Haruma; N Ohtsu; T Tsuda; Masaharu Yoshihara; Koji Sumii; Goro Kajiyama; Masahiko Nishiyama; T Hirai
[The risk factors of lymph node metastasis in submucosal invasive gastric carcinoma--assessment of the indication for endoscopic treatment].
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 1994;91(9):1399-406.
1993: H Kawami; K Yoshida; A Ohsaki; K Kuroi; Masahiko Nishiyama; Tetsuya Toge
Stromelysin-3 mRNA expression and malignancy: comparison with clinicopathological features and type IV collagenase mRNA expression in breast tumors.
Anticancer research 1993;13(6A):2319-23.
1993: Masahiko Nishiyama; S Saeki; Kenjiro Aogi; N Hirabayashi; Tetsuya Toge
[Mitomycin C and its bioreduction: relevance of NAD(P)H: quinone oxidoreductase activity to mitomycin C-induced DNA damage and cytotoxicity].
Gan to kagaku ryoho. Cancer & chemotherapy 1993;20(8):1037-41.
1993: Masahiko Nishiyama; S Saeki; Kenjiro Aogi; N Hirabayashi; Tetsuya Toge
Relevance of DT-diaphorase activity to mitomycin C (MMC) efficacy on human cancer cells: differences in in vitro and in vivo systems.
International journal of cancer. Journal international du cancer 1993;53(6):1013-6.
1992: Masahiko Nishiyama; Kenjiro Aogi; S Saeki; Ryungsa Kim; K Kuroi; Yoshiyuki Yamaguchi; Tetsuya Toge
A role for plasma membrane potential in doxorubicin--induced cytotoxicity.
Anticancer research 1992;12(3):849-52.
1992: Ryungsa Kim; N Hirabayashi; Masahiko Nishiyama; K Jinushi; Tetsuya Toge; K Okada
Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
International journal of cancer. Journal international du cancer 1992;50(5):760-6.
1992: Ryungsa Kim; N Hirabayashi; Masahiko Nishiyama; K Jinushi; Tetsuya Toge; K Okada
Factors contributing to adriamycin sensitivity in human xenograft tumors: the relationship between expression of the MDR1, GST-pi and topoisomerase II genes and tumor sensitivity to adriamycin.
Anticancer research 1992;12(1):241-5.
1991: Masahiko Nishiyama; Kenjiro Aogi; S Saeki; N Hirabayashi; Tetsuya Toge
[Combination of a biscoclaurine alkaloid, cepharanthine, and anticancer agents: effects and mechanism in human gastric and pancreatic carcinoma cell lines].
Gan to kagaku ryoho. Cancer & chemotherapy 1991;18(14):2429-33.
1991: Ryungsa Kim; N Hirabayashi; Masahiko Nishiyama; Kenjiro Aogi; Tetsuya Toge
Clinical significance of P-glycoprotein expression analyzed by immunohistochemical staining in cancer tissues.
The Japanese journal of surgery 1991;21(5):590-3.
1991: Ryungsa Kim; N Hirabayashi; Masahiko Nishiyama; T Yorishima; Tetsuya Toge; K Okada
mRNA expression of topoisomerase II in human tumors and normal tissues.
The Japanese journal of surgery 1991;21(5):587-9.
1991: Ryungsa Kim; N Hirabayashi; Masahiko Nishiyama; S Saeki; Tetsuya Toge; K Okada
Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin.
Anticancer research 1991;11(1):429-31.
1990: K Jinushi; N Hirabayashi; Y Kirihara; S Takagami; K Ryuji; T Yorishima; Masahiko Nishiyama; Y Noso; Tetsuya Toge
[Clinical studies of in vitro chemosensitivity test evaluated by ATP assay of gastrointestinal cancer].
Gan to kagaku ryoho. Cancer & chemotherapy 1990;17(11):2235-9.
1990: Ryungsa Kim; T Saeki; S Takagami; Y Kirihara; K Jinushi; Masahiko Nishiyama; M Niimoto; T Hattori; K Okada
Prediction of the resistance of human tumors to adriamycin by chemosensitivity tests and DNA analysis of the multidrug resistance gene.
The Japanese journal of surgery 1990;20(2):192-6.
1990: M Niimoto; T Saeki; M Toi; Masahiko Nishiyama; T Hirai; E Yanagawa; T Hattori
Prospective randomized controlled study on bestatin in resectable gastric cancer--third report.
The Japanese journal of surgery 1990;20(2):186-91.
1989: Masahiko Nishiyama; Ryungsa Kim; K Jinushi; S Takagami; Y Kirihara; Tetsuya Toge
Antitumor effect of KW2149, a new mitomycin derivative, administered by different modalities.
In vivo (Athens, Greece) 1989;3(6):375-9.
1989: E Yanagawa; Masahiko Nishiyama; T Saeki; Ryungsa Kim; K Jinushi; Y Kirihara; S Takagami; M Niimoto; T Hattori
Chemosensitivity tests in colorectal cancer patients.
The Japanese journal of surgery 1989;19(4):432-8.
1989: Masahiko Nishiyama; M Hirono; S Takagami; Ryungsa Kim; T Saeki; Y Kirihara; K Jinushi; E Yanagawa; Tetsuya Toge; M Niimoto
The histological assessment and evaluation of a 4 day subrenal capsule assay by the percentage inhibition of DNA/protein.
The Japanese journal of surgery 1989;19(4):403-9.
1989: S Takagami; Masahiko Nishiyama; Ryungsa Kim; Y Kirihara; K Jinushi; K Saeki; T Saeki; Y Nosoh; M Niimoto; T Hattori
[Comparative study on the anticancer activities of KW2149 and mitomycin C against human tumor xenografts using subrenal capsule assay].
Gan to kagaku ryoho. Cancer & chemotherapy 1989;16(6):2189-93.
1989: T Saeki; K Jinushi; Ryungsa Kim; Y Kirihara; S Takagami; Masahiko Nishiyama; K Saeki; M Niimoto; T Hattori
[Comparison of succinic dehydrogenase inhibition test with adenosine triphosphate inhibition assay for human solid tumors as in vitro chemosensitivity tests].
Gan to kagaku ryoho. Cancer & chemotherapy 1989;16(5):2025-30.
1988: Masahiko Nishiyama; S Takagami; Ryungsa Kim; Y Kirihara; T Saeki; K Jinushi; M Niimoto; T Hattori
[Inhibition of thymidylate synthetase and antiproliferative effect by 1-hexylcarbamoyl-5-fluorouracil].
Gan to kagaku ryoho. Cancer & chemotherapy 1988;15(11):3109-13.
1988: Masahiko Nishiyama; Ryungsa Kim; T Saeki; S Takagami; Y Kirihara; K Jinushi; Tetsuya Toge; M Niimoto; T Hattori
[Anticancer activities of a new mitomycin derivative KW 2149, against human tumors xenografted into nude mice].
Gan to kagaku ryoho. Cancer & chemotherapy 1988;15(11):3133-7.
1988: Masahiko Nishiyama; S Takagami; Y Kirihara; T Saeki; K Niimi; Y Nosoh; N Hirabayashi; M Niimoto; T Hattori
The indications of chemosensitivity tests against various anticancer agents.
The Japanese journal of surgery 1988;18(6):647-52.
1988: Masahiko Nishiyama; S Takagami; Y Kirihara; T Saeki; N Hirabayashi; Y Nosoh; M Niimoto; T Hattori
The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
The Japanese journal of surgery 1988;18(6):725-8.
1988: Masahiko Nishiyama; S Takagami; Y Kirihara; T Saeki; K Niimi; Ryungsa Kim; K Jinushi; Tetsuya Toge; M Niimoto; T Hattori
[Combined effects of interferon alpha-A/D with fluoropyrimidine derivatives in the subrenal capsule assay].
Gan to kagaku ryoho. Cancer & chemotherapy 1988;15(8):2285-90.
1988: T Saeki; H Kuninobu; H Kodama; Masahiko Nishiyama; K Yoshinaka; Tetsuya Toge; M Niimoto; T Hattori
[Multidisciplinary treatment of unresectable liver cancer].
Gan to kagaku ryoho. Cancer & chemotherapy 1988;15(8 Pt 2):2583-9.
1988: K Yoshinaka; T Tanaka; S Takagami; T Saeki; Masahiko Nishiyama; Tetsuya Toge; M Niimoto; T Hattori
[Prospective randomized controlled study of bestatin in gastric cancer surgery].
Gan to kagaku ryoho. Cancer & chemotherapy 1988;15(3):493-8.
1988: Masahiko Nishiyama; K Niimi; S Takagami; N Hirabayashi; M Yamaguchi; T Saeki; K Yoshinaka; D C Wang; M Niimoto; T Hattori
Combined effects of UFT with other anticancer agents using in vivo chemosensitivity tests.
The Japanese journal of surgery 1988;18(1):93-7.
1987: Y Noso; K Niimi; Masahiko Nishiyama; N Hirabayashi; Tetsuya Toge; M Niimoto; T Hattori
Clinical studies on a new screening assay for anticancer agents using nude mice and isotopic evaluation.
Cancer research 1987;47(23):6418-22.
1987: N Hirabayashi; Masahiko Nishiyama; K Niimi; M Yamaguchi; Tetsuya Toge; M Niimoto; T Hattori
Effect of oxygen tension on the antitumor activity of mitomycin C assayed by human tumor clonogenic assay.
The Japanese journal of surgery 1987;17(5):402-6.
1987: M Niimoto; Masahiko Nishiyama; S Takagami; K Niimi; T Saeki; K Yoshinaka; T Hattori
[Clinical trials of the subrenal capsule assay].
Gan to kagaku ryoho. Cancer & chemotherapy 1987;14(8):2444-9.
1987: Y Nosoh; Tetsuya Toge; K Niimi; Masahiko Nishiyama; N Hirabayashi; K Nakanishi; M Niimoto; T Hattori
Experimental studies on the combined effects of alpha and gamma interferons against human tumor xenografts transplanted into nude mice.
The Japanese journal of surgery 1987;17(3):168-73.
1987: K Niimi; Masahiko Nishiyama; N Hirabayashi; M Yamaguchi; Y Nosoh; D C Wang; Tetsuya Toge; M Niimoto; T Hattori
[In vivo chemosensitivity test for UFT and FT-207. II. Chemosensitivity test on human tumor xenografts transplanted in nude mice].
Gan to kagaku ryoho. Cancer & chemotherapy 1987;14(5 Pt 1):1281-5.
1987: Y Nosoh; Masahiko Nishiyama; K Niimi; N Hirabayashi; Tetsuya Toge; M Niimoto; T Hattori
Antitumor activities of KW-2152, a new isoquinon agent, against human tumor xenografts transplanted into nude mice.
The Japanese journal of surgery 1987;17(2):146-9.
1987: N Hirabayashi; Y Noso; K Niimi; Masahiko Nishiyama; M Yamaguchi; Tetsuya Toge; M Niimoto; T Hattori
Comparative studies on in vitro human tumor clonogenic assay (HTCA) and in vivo nude mouse-isotope assay (NM-IA).
The Japanese journal of surgery 1987;17(2):104-9.
1987: Masahiko Nishiyama; K Niimi; M Yamaguchi; N Hirabayashi; Y Nosoh; T Tohge; M Niimoto; T Hattori
[In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay].
Gan to kagaku ryoho. Cancer & chemotherapy 1987;14(1):109-13.
1986: Masahiko Nishiyama; Y Noso; N Hirabayashi; M Yamaguchi; Tetsuya Toge; M Niimoto; T Hattori
Prediction of individual tumor chemosensitivity in subrenal capsule assay.
The Japanese journal of surgery 1986;16(4):257-61.
1986: Masahiko Nishiyama; Y Noso; M Yamaguchi; N Hirabayashi; Tetsuya Toge; M Niimoto; T Hattori
[Sensitivity test of anticancer agents by subrenal capsule assay (SRC assay). II--Determination of tumor sensitivity by percentage inhibition of DNA protein].
Gan to kagaku ryoho. Cancer & chemotherapy 1986;13(2):275-9.